The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd
Image: Alpine Immune Sciences
The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania. Following the poster presentation, the Company will host an investor event after the close of the market.
American Society of Nephrology – Kidney Week 2023
Date/Time: Thursday, November 2, 2023, 10:00 am – 12:00 pm ET
Poster Title: Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)
Poster Board Number: TH-PO1125
Session Name: Late-Breaking Posters
Location: Exhibit Hall, Pennsylvania Convention Center, Philadelphia
Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium
Investor Event
Date/Time: Thursday, November 2, 2023, at 4:30 pm – 5:30 pm ET
Link to Webcast: https://bit.ly/48Gk8yH
Source: Company Press Release